期刊文献+

局部用咪喹莫特泡囊凝胶剂的制备、表征及皮内滞留效应 被引量:1

Preparation,characterization and intracutaneous retention effect of imiquimod niosomal gel for topical application
原文传递
导出
摘要 目的:制备并表征局部用咪喹莫特泡囊凝胶剂,考察药物皮内滞留效应。方法:制备并表征咪喹莫特泡囊凝胶剂,离体鼠皮透皮实验考察药物皮内滞留量和透过量,切片观察药物皮内分布。结果:泡囊的平均粒径197.2 nm,Zeta电位-42.97 m V,包封率27.44%;泡囊凝胶剂体外释放t1/2与泡囊相似,但为凝胶剂的4.94倍和市售乳膏的3.83倍,12 h透过药量均比凝胶剂和市售乳膏小一半,单位面积皮内药物滞留量约为它们的2倍,切片显示药库效应显著。结论:泡囊凝胶剂具缓释作用和药库效应,可增加皮内滞留,减少角质层拦截和透过皮肤的药量,将有利于皮肤病的治疗,并可降低局部刺激性和全身毒性的风险。 Objective: To prepare and characterize imiquimod niosomal gel for topical application, and in- vestigate the intracutaneous retention effect. Methods: Imiquimod niomosal gel was prepared and characterized. The amount of imiquimod permeated and within the skin was investigated by transdermal studies on the ex-vivo rat skin. Intradermal drug distribution in the skin section was observed with confocal laser scanning microscopy. Results: The average particle size, zeta-potential and entrapment efficiency of the imiquimod niosomes were 197.2 nm, - 42.97 mV and 27.44% , respectively. The tl/2 value of drug release from the niosomal gel in vitro was similar to that from the niosomes (P 〉 0.5) , but was 4.94 and 3.83 folds as that from the gel and commercial cream, respectively (P 〈 0.01 ). The amount of drug permeated from niosomal gel into the skin in 12 h was 50% less than that from the gel and commercial cream, while the amount of drug retention in the skin was about 2 times more than that of the gel and commercial cream. The significant reservoir effect was also demonstrated by the section observation. Conclusion: Imiquimod niosomal gel shows a sustained release property and a reservoir effect for the drug, making high retention of drug in the skin, and reducing the drug in stratum interception and skin transmission. Therefore, it would be helpful for therapy of dermatosis, and reduce the topical irritation and the systemic toxicity.
机构地区 苏州大学药学院
出处 《中国新药杂志》 CAS CSCD 北大核心 2015年第1期97-101,共5页 Chinese Journal of New Drugs
基金 国家自然科学基金(81273462)
关键词 泡囊凝胶剂 咪喹莫特 体外释放 皮内滞留 药库效应 niosomal gel imiquimod drug release in vitro intraeutaneous accumulation reservoir effect
  • 相关文献

参考文献9

  • 1SAUDER DN. Immunomodulatory and pharmacologic proper- ties of imiquimod [ J ]. J Am Acad Dermatol,2000,43 ( Suppl 1 ) : $6 - S11.
  • 2CANTISANI C,LAZIC T,RICHETTA AG, et al. Imiquimod 5% cream use in dermatology, side effects and recent patents[J]. Re- cent Pat Inflamm Allergy Drug Discov,2012,6 ( 1 ) : 65 - 69.
  • 3ROSENBLATT A, DE CAMPOS GUIDI HG. Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases [ J]. Int J STD AIDS, 2012,23 (12) :909 -910.
  • 4AZEEM A,ANWER MK,TALEGAONKAR S. Niosomes in sus- tained and targeted drug delivery: some recent advances [ J ]. J Drug Target,2009,17 ( 9 ) :671 - 689.
  • 5VERMA DD,VERMA S, BLUME G,et al. Particle size of lipo- somes influences dermal delivery of substances into skin [ J]. lnt J Pharm ,2003,258 ( 1 - 2) : 141.
  • 6郑俊民.药用高分子材料[M].北京:中国医药科技出版社,2000:150.
  • 7刘慧敏,杨红,刘洵含,周天一,黄娟.氟尿嘧啶泡囊凝胶剂的体外透皮试验[J].中国医院药学杂志,2011,31(17):1414-1416. 被引量:1
  • 8LI C,ZHANG X, HUANG X,et al. Preparation and characteriza- tion of fexible nanoliposomes loaded with daptomycin,a novel an- tibiotic,for topical skin therapy[ J]. Int J Nanomedicine,2013, 8:1285 - 1292.
  • 9杨红,周映聪,邓安平,肖波,黄晶晶,晁若冰.顺铂隐形泡囊的研制及表面连接蛋白质前后的性质比较[J].中国新药杂志,2009,18(7):668-671. 被引量:1

二级参考文献15

  • 1陈永,杨红,陆彬,李玫,宗太丽.肺靶向顺铂泡囊的研制与体外性质的评价[J].华西药学杂志,2008,23(2):129-132. 被引量:8
  • 2柯爱武,李羲.聚乙二醇修饰免疫脂质体研究进展[J].国外医学(预防.诊断.治疗用生物制品分册),2004,27(4):170-174. 被引量:7
  • 3BOSCH ME,SANCHEZ A J, ROJAS FS,et al. Analytical methodologies for the determination of cisplatim [ J ]. J Pharm Biomed Anal,2008,47 ( 3 ) :451 - 459.
  • 4JISKOOT W,HOVEN AMV,DE KONING AAM,et al. Purification and stabilization of a poorly soluble mouse IgG3 monoclonal antibody [ J ]. Immunological Methods, 1991,138 ( 1 ) : 181 - 189.
  • 5DEVARAJ GN,PARAKH SR,DEVRAJ R,et al. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol[J]. J Colloid Interface Sci, 2002,251 ( 2 ) : 360 - 365.
  • 6VANGALA A,BRAMWELL VW,MCNEIL S,et al. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen [ J ]. J Control Release ,2007,119 ( 1 ) : 102 - 110.
  • 7MOKHTAR M,SAMMOUR OA,HAMMAD MA,et al. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes [ J ]. Int J Pharm, 2008 : 361 ( 1-2 ) : 104 - 111.
  • 8GIANASI E,COCIANCICH F, UCHEGBU IF,et al. Pharmaceutical and biological characterisation of a doxorubicin-polymer conjugate (PKI) entrapped in sorbitan monostearate Span 60 niosomes[J], Int J Pharm,1997 ,148( 2 ) :139 -148.
  • 9Sharon Levy, MD, Katharine Furst, et al. A pharnlacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in t)a tients with Actinic Keratosis [J]. Clin Ther, 2001, 23 (6):908-920.
  • 10Venuganti W, Perumal OP. Effect of poly (amidoamine) (PAMAM)dendrimer on skin permeation of 5- fluorouracil[J]. Int J Pharm, 2008, 361 : 230-238.

共引文献4

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部